Kadimastem Ltd

Tel Aviv Stock Exchange KDST.TA

Kadimastem Ltd Market Capitalization on January 14, 2025: USD 18.18 M

Kadimastem Ltd Market Capitalization is USD 18.18 M on January 14, 2025, a 134.98% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Kadimastem Ltd 52-week high Market Capitalization is USD 18.18 M on January 14, 2025, which is 0.00% below the current Market Capitalization.
Kadimastem Ltd 52-week low Market Capitalization is USD 6.18 M on April 16, 2024, which is -65.98% below the current Market Capitalization.
Kadimastem Ltd average Market Capitalization for the last 52 weeks is USD 9.88 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Tel Aviv Stock Exchange: KDST.TA

Kadimastem Ltd

CEO	Mr. Ronen Twito CPA
IPO Date	June 13, 2013
Location	Israel
Headquarters	Pinchas Sapir 7
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.

Key trends

Past 5 years